Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Large Growth in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 17,700 shares, an increase of 785.0% from the February 13th total of 2,000 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 301,300 shares, the days-to-cover ratio is presently 0.1 days.

Appili Therapeutics Stock Up 2.9 %

Shares of APLIF opened at $0.03 on Thursday. Appili Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.05. The stock has a market cap of $3.03 million, a PE ratio of -1.25 and a beta of -0.55. The business’s 50-day moving average price is $0.02 and its 200-day moving average price is $0.02.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.